Literature DB >> 23316019

Individual hematopoietic stem cells in human bone marrow of patients with aplastic anemia or myelodysplastic syndrome stably give rise to limited cell lineages.

Takamasa Katagiri1, Hiroshi Kawamoto, Takashi Nakakuki, Ken Ishiyama, Mariko Okada-Hatakeyama, Shigeki Ohtake, Yu Seiki, Kohei Hosokawa, Shinji Nakao.   

Abstract

Mutation of the phosphatidylinositol N-acetylglucosaminyltransferase subunit A (PIG-A) gene in hematopoietic stem cells (HSCs) results in the loss of glycosylphosphatidylinositol-anchored proteins (GPI-APs) on HSCs, but minimally affects their development, and thus can be used as a clonal maker of HSCs. We analyzed GPI-APs expression on six major lineage cells in a total of 574 patients with bone marrow (BM) failure in which microenvironment itself is thought to be unaffected, including aplastic anemia (AA) or myelodysplastic syndrome (MDS). GPI-APs-deficient (GPI-APs(-) ) cells were detected in 250 patients. Whereas the GPI-APs(-) cells were seen in all six lineages in a majority of patients who had higher proportion ([dbmtequ]3%) of GPI-APs(-) cells, they were detected in only limited lineages in 92.9% of cases in the lower proportion (<3%) group. In all 250 cases, the same lineages of GPI-APs(-) cells were detected even after 6-18-month intervals, indicating that the GPI-APs(-) cells reflect hematopoiesis maintained by a self-renewing HSC in most of cases. The frequency of clones with limited lineages seen in mild cases of AA was similar to that in severe cases, and clones with limited lineages were seen even in two health volunteer cases. These results strongly suggest most individual HSCs produce only restricted lineages even in a steady state. While this restriction could reflect heterogeneity in the developmental potential of HSCs, we propose an alternative model in which the BM microenvironment is mosaic in supporting commitment of progenitors toward distinct lineages. Our computer simulation based on this model successfully recapitulated the observed clinical data.
Copyright © 2012 AlphaMed Press.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23316019     DOI: 10.1002/stem.1301

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  6 in total

1.  Paroxysmal nocturnal hemoglobinuria induced by the occurrence of BCR-ABL in a PIGA mutant hematopoietic progenitor cell.

Authors:  R Tominaga; T Katagiri; K Kataoka; K Kataoka; R K C Wee; A Maeda; H Gomyo; I Mizuno; T Murayama; S Ogawa; S Nakao
Journal:  Leukemia       Date:  2015-10-06       Impact factor: 11.528

2.  T Cell Transcriptomes from Paroxysmal Nocturnal Hemoglobinuria Patients Reveal Novel Signaling Pathways.

Authors:  Kohei Hosokawa; Sachiko Kajigaya; Keyvan Keyvanfar; Wangmin Qiao; Yanling Xie; Danielle M Townsley; Xingmin Feng; Neal S Young
Journal:  J Immunol       Date:  2017-06-19       Impact factor: 5.422

3.  Whole transcriptome sequencing identifies increased CXCR2 expression in PNH granulocytes.

Authors:  Kohei Hosokawa; Sachiko Kajigaya; Keyvan Keyvanfar; Wangmin Qiao; Yanling Xie; Angelique Biancotto; Danielle M Townsley; Xingmin Feng; Neal S Young
Journal:  Br J Haematol       Date:  2017-02-01       Impact factor: 6.998

Review 4.  When does a PNH clone have clinical significance?

Authors:  Daria V Babushok
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

5.  HLA associations, somatic loss of HLA expression, and clinical outcomes in immune aplastic anemia.

Authors:  Yoshitaka Zaimoku; Bhavisha A Patel; Sharon D Adams; Ruba Shalhoub; Emma M Groarke; Audrey Ai Chin Lee; Sachiko Kajigaya; Xingmin Feng; Olga Julia Rios; Holly Eager; Lemlem Alemu; Diego Quinones Raffo; Colin O Wu; Willy A Flegel; Neal S Young
Journal:  Blood       Date:  2021-12-30       Impact factor: 25.476

6.  Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag.

Authors:  Yoshitaka Zaimoku; Bhavisha A Patel; Ruba Shalhoub; Emma M Groarke; Xingmin Feng; Colin O Wu; Neal S Young
Journal:  Haematologica       Date:  2022-01-01       Impact factor: 9.941

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.